For example, breast cancer-positive for estrogen receptor shows increased metastatic likelihood up to 20 years after the removal of the primary tumor, while estrogen receptor-negative subtypes either relapse within the first 5 years or don’t relapse at all [3,4]. Here, ESR1 is linked to breast carcinoma.